[Evaluation of carbenoxolone in long term treatment of recurrent duodenal ulcer (author's transl)].
A double-blind randomized trial was performed in order to evaluate the efficacy of carbenoxolone (Biogastron duodenal) in reducing recurrences of duodenal ulcer. Eighty-one patients with endoscopically proven recurrent duodenal ulcer (at least a painful ulcer episodes within the past two years) were randomized. Fourty-six were assigned to carbenoxolon (50 mg Biogastron duodenal three times daily) and 35 to placebo. Every month the patients were seen in the out-patient department and asked for symptoms, especially typical pain, and - if indicated - examined by gastrofiberscopy. After about two years, 72 percent of the patients treated with carbenoxolone and 66 percent ot the placebo group remained without recurrence. The difference is not significant.